Alaunos Therapeutics (TCRT) Cash & Equivalents (2009 - 2026)

Alaunos Therapeutics (TCRT) has 18 years of Cash & Equivalents data on file, last reported at $354000.0 in Q1 2026.

• Quarterly Cash & Equivalents rose 10.97% year-over-year to $354000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $354000.0 (up 10.97% YoY) and the FY2025 annual result came in at $1.4 million, up 26.95% from the prior year.
• Cash & Equivalents eased to $354000.0 in Q1 2026, from $1.4 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $68.3 million in Q1 2022 to a low of $319000.0 in Q1 2025.
• A 5-year average of $16.5 million and a median of $4.1 million in 2024 frame the typical range for Cash & Equivalents.
• The widest YoY moves for Cash & Equivalents: up 26.95% in 2025, down 92.3% in 2025.
• Tracing TCRT's Cash & Equivalents over 5 years: stood at $39.1 million in 2022, then plunged by 84.48% to $6.1 million in 2023, then tumbled by 82.0% to $1.1 million in 2024, then climbed by 26.95% to $1.4 million in 2025, then sank by 74.44% to $354000.0 in 2026.
• The last three Cash & Equivalents figures came in at $354000.0 (Q1 2026), $1.4 million (Q4 2025), and $1.9 million (Q3 2025), per Business Quant data.